MIV Therapeutics says independent research backs safety of stent coating technology

New York, June 5 - MIV Therapeutics said the safety and biocompatibility of its proprietary Hydroxyapatite vascular stent coating technology has received pivotal independent confirmation in a new study conducted by a team of researchers in Italy and published in the Journal of Biomedical Materials Research.

MIV quoted the article as saying: "In conclusion, the present findings indicate that HA nanocrystals exhibit high biocompatibility for microvascular endothelium. In the presence of HAp nanocrystals endothelial cells maintain biochemical markers of healthy endothelium. They do not acquire a proinflammatory or thrombogenic phenotype, but express markers of functioning endothelium that might contribute to angiogenesis."

MIV is a Vancouver, B.C., company developing advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.